You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Both companies have made their products available on Azure, and Curoverse is collaborating with Microsoft on benchmarking tools for analysis pipelines.
In a JNCCN paper, the investigators discussed their efforts to comprehensively characterize a single patient's breast tumor and test potential treatments.
The Center for Data Driven Discovery in Biomedicine is a joint project of CHOP Research Institute and CHOP's Department of Biomedical Health and Informatics.
Under the terms of the agreement, DNAnexus will make Sapio's LIMS software available on its genomics infrastructure.
CyVerse, the developers believe, better expresses the platform's capacity to provide data management and computation to researchers across multiple scientific disciplines.
New bioinformatics businesses bloomed over the past year in spite of a challenging market and encroachment from instrument vendors and other larger entities.
The partners are working to implement the University of Cologne's QuickNGS software on Bluebee's cloud-based platform
SAP has released products for integrating and analyzing structured and unstructured clinical and genomic datasets, and supporting patient cohort analysis.
Participants in the three-day hackathon, to be held early next year, will develop tools for analyzing NGS data in the context of specific research questions.
Maverix Biomics and Diagnomics have received CLIA validation for their pre-natal molecular diagnostic on a next-generation sequencing platform.
A UK study on mixing SARS-CoV-2 vaccines is expanding to include vaccines developed by additional companies, according to the Guardian.
According to Science, the US National Academy of Sciences is poised to eject two members accused of sexual harassment.
In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.